SURMOUNT-3: Tirzepatide shows total mean weight loss of 26.6% from study entry over 84 weeksDetailed results from the phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with...
Carmot’s CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetesCarmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for...
Novo Nordisk to end semaglutide kidney study early due to strong efficacy signalsNovo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
Why obesity leads to a complex inflammatory response inside adipose tissueA study by Dr Lindsey Muir, a research assistant professor in the Department of Computational Medicine and Bioinformatics, and colleagues...
Allurion completes AUDACITY trial enrolment for Allurion BalloonAllurion Technologies has completed patient enrolment in its AUDACITY trial, a randomised, pivotal controlled trial designed to support...
Journal Watch 11/10/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure22 hours ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity22 hours ago